# Femasys Inc: overview
FEMY · Nasdaq · CIK 1339005 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31
Pages: [Overview](/companies/femy.md) · [Financials](/companies/femy/financials.md) · [Filings](/companies/femy/filings.md) · [Insiders](/companies/femy/insiders.md)
Latest reported revenue: [$331.8k](/filings/0001140361-26-033157.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001140361-26-033157).
## Last eight quarters
| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [555](/filings/0001140361-25-042308.md) | [582 d](/filings/0001140361-26-012375.md) | [341](/filings/0001140361-26-020115.md) | [409](/filings/0001140361-26-033157.md) | [729](/filings/0001140361-25-042308.md) | [813 d](/filings/0001140361-26-012375.md) | [425](/filings/0001140361-26-020115.md) | [332](/filings/0001140361-26-033157.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(922.4%)](/filings/0001140361-25-042308.md) | [(812.0%) d](/filings/0001140361-26-012375.md) | [(1600.1%)](/filings/0001140361-26-020115.md) | [(941.1%)](/filings/0001140361-26-033157.md) | [(500.9%)](/filings/0001140361-25-042308.md) | [(568.3%) d](/filings/0001140361-26-012375.md) | [(994.0%)](/filings/0001140361-26-020115.md) | [(1526.7%)](/filings/0001140361-26-033157.md) |
| Net margin | % | [(974.7%)](/filings/0001140361-25-042308.md) | [(881.0%) d](/filings/0001140361-26-012375.md) | [(1727.9%)](/filings/0001140361-26-020115.md) | [(1120.5%)](/filings/0001140361-26-033157.md) | [(575.1%)](/filings/0001140361-25-042308.md) | [(485.7%) d](/filings/0001140361-26-012375.md) | [199.1%](/filings/0001140361-26-020115.md) | [(1346.8%)](/filings/0001140361-26-033157.md) |
| Diluted EPS | $ per share | [(0.24)](/filings/0001140361-25-042308.md) | not reported | [(0.23)](/filings/0001140361-26-020115.md) | [(3.18)](/filings/0001140361-26-033157.md) | [(0.10)](/filings/0001140361-25-042308.md) | not reported | [0.00](/filings/0001140361-26-020115.md) | [(1.33)](/filings/0001140361-26-033157.md) |
| Free cash flow | $k | [(5,883) d](/filings/0001140361-25-042308.md) | [(5,181) d](/filings/0001140361-26-012375.md) | [(4,862)](/filings/0001140361-26-020115.md) | [(4,447) d](/filings/0001140361-26-033157.md) | [(5,582) d](/filings/0001140361-25-042308.md) | [(4,325) d](/filings/0001140361-26-012375.md) | [(4,223)](/filings/0001140361-26-020115.md) | [(3,945) d](/filings/0001140361-26-033157.md) |
- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.
## Last five fiscal years
| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1.2](/filings/0001140361-23-035663.md) | [1.2](/filings/0001140361-24-016230.md) | [1.1](/filings/0001140361-25-010598.md) | [1.6](/filings/0001140361-26-012375.md) | [2.3](/filings/0001140361-26-012375.md) |
| Gross margin | % | [68.6%](/filings/0001140361-23-035663.md) | [63.4%](/filings/0001140361-23-035663.md) | not reported | not reported | not reported |
| Operating margin | % | [(706.7%)](/filings/0001140361-23-035663.md) | [(961.7%)](/filings/0001140361-24-016230.md) | [(1353.4%)](/filings/0001140361-25-010598.md) | [(1091.8%)](/filings/0001140361-26-012375.md) | [(767.0%)](/filings/0001140361-26-012375.md) |
| Net margin | % | [(639.0%)](/filings/0001140361-23-035663.md) | [(944.6%)](/filings/0001140361-24-016230.md) | [(1329.1%)](/filings/0001140361-25-010598.md) | [(1155.0%)](/filings/0001140361-26-012375.md) | [(812.3%)](/filings/0001140361-26-012375.md) |
| Diluted EPS | $ per share | [(1.12)](/filings/0001140361-23-035663.md) | [(0.96)](/filings/0001140361-24-016230.md) | [(0.93)](/filings/0001140361-25-010598.md) | [(0.85)](/filings/0001140361-26-012375.md) | [(0.47)](/filings/0001140361-26-012375.md) |
| Free cash flow | $m | [(8.2)](/filings/0001140361-23-035663.md) | [(11.1)](/filings/0001140361-24-016230.md) | [(11.4)](/filings/0001140361-25-010598.md) | [(20.2)](/filings/0001140361-26-012375.md) | [(19.2)](/filings/0001140361-26-012375.md) |
- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.
## Insider purchases and sales
The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/femy/insiders.md)
None in coverage.
## Funds that report holding it
From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)
| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Dauntless Investment Group, LLC](/funds/2044285.md) | 2026-06-30 | $7.8m | 1,867,987 | | New +1,867,987 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $260.1k | 62,232 | | New +62,232 |
| [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $219.5k | 52,511 | | New +52,511 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $129.3k | 30,920 | | New +30,920 |
| [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $78.5k | 18,777 | | New +18,777 |
| [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $70.7k | 16,921 | | New +16,921 |
| [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $52.2k | 12,492 | | New +12,492 |
| [OSAIC HOLDINGS, INC.](/funds/1677044.md) | 2026-06-30 | $10.0k | 2,397 | | New +2,397 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $7.5k | 1,784 | | New +1,784 |
| [NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO](/funds/1141802.md) | 2026-06-30 | $4.2k | 1,000 | | New +1,000 |
## Recent filings
[All 333 filings](/companies/femy/filings.md)
| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-17 | 20:30 ET | [SCHEDULE 13D](/filings/0001104659-26-097888.md) | Ownership report, active investor | 0001104659-26-097888 |
| 2026-08-14 | 20:28 ET | [10-Q](/filings/0001140361-26-033157.md) | Quarterly report, period 2026-06-30 | 0001140361-26-033157 |
| 2026-08-14 | 20:11 ET | [8-K](/filings/0001140361-26-033145.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001140361-26-033145 |
| 2026-08-11 | 20:40 ET | [8-K](/filings/0001140361-26-032247.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001140361-26-032247 |
| 2026-06-24 | 20:05 ET | [8-K](/filings/0001140361-26-026239.md) | 5.07 Shareholder vote results | 0001140361-26-026239 |
| 2026-06-24 | 13:35 ET | [8-K](/filings/0001140361-26-026169.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-026169 |
| 2026-06-05 | 20:06 ET | [8-K](/filings/0001140361-26-024265.md) | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001140361-26-024265 |
| 2026-06-04 | 13:00 ET | [8-K](/filings/0001140361-26-023955.md) | 7.01 Regulation FD disclosure | 0001140361-26-023955 |
| 2026-05-13 | 20:48 ET | [8-K](/filings/0001140361-26-021081.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-021081 |
| 2026-05-08 | 20:45 ET | [10-Q](/filings/0001140361-26-020115.md) | Quarterly report, period 2026-03-31 | 0001140361-26-020115 |
## Latest annual report
[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001140361-26-012375.md), filed Mar 31, 2026.
## Forecast league
Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/3e2b3ccf-ef3c-46a6-8df4-4635649276bc)
## About the filer
- CIK: 1339005
- Tickers: FEMY
- Exchange: Nasdaq
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: DE
- Filer category: Non-accelerated filer
Smaller reporting company
Emerging growth company
Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:37 ET. No prices; not investment advice.